These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Assessing the success probability of a Phase III clinical trial based on Phase II data. Su Z Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180 [TBL] [Abstract][Full Text] [Related]
44. On design considerations and randomization-based inference for community intervention trials. Gail MH; Mark SD; Carroll RJ; Green SB; Pee D Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140 [TBL] [Abstract][Full Text] [Related]
45. Adaptive designs based on the truncated product method. Neuhäuser M; Bretz F BMC Med Res Methodol; 2005 Sep; 5():30. PubMed ID: 16171518 [TBL] [Abstract][Full Text] [Related]
46. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate. Timmesfeld N; Schäfer H; Müller HH Stat Med; 2007 May; 26(12):2449-64. PubMed ID: 17080491 [TBL] [Abstract][Full Text] [Related]
47. Sample size and the probability of a successful trial. Chuang-Stein C Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428 [TBL] [Abstract][Full Text] [Related]
48. The clinical significance of statistical significance. Kane RC Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874 [TBL] [Abstract][Full Text] [Related]
49. Increasing the sample size when the unblinded interim result is promising. Chen YH; DeMets DL; Lan KK Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876 [TBL] [Abstract][Full Text] [Related]
50. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials. Daimon T Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944 [TBL] [Abstract][Full Text] [Related]
51. How many do I need? Basic principles of sample size estimation. Devane D; Begley CM; Clarke M J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124 [TBL] [Abstract][Full Text] [Related]
52. Sequential designs for phase III clinical trials incorporating treatment selection. Stallard N; Todd S Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100 [TBL] [Abstract][Full Text] [Related]
53. Drug research: from the idea to the product. Kuhlmann J Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711 [TBL] [Abstract][Full Text] [Related]
54. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences. Schäfer H; Müller HH Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350 [TBL] [Abstract][Full Text] [Related]
55. Alternative designs of phase II trials considering response and toxicity. Jin H Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744 [TBL] [Abstract][Full Text] [Related]